CDKN2C Antibody

1. Low P18 expression is associated with multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors. PMID: 29134609
2. Cycling hypoxia could induce significant changes in CLDN1 and CLDN7 expression in nasopharyngeal cancer cells, indirectly regulation P18 expression and affecting cell invasion/proliferation. PMID: 28055967
3. genetic association studies in population in Houston TX: Data suggest that CDKN2C copy number variations are associated with sporadic medullary thyroid carcinoma; these associations include presence of distant metastasis at presentation and decreased overall survival. PMID: 27610696
4. CDKN2C gene deletion is associated with plasma cell post-transplantation lymphoproliferative disorders. PMID: 27750397
5. Our study suggests that p18 is a limiting factor for the noncanonical HSC differentiation path in lymphoid lineages. PMID: 27287689
6. CDKN2C inactivation contributes to the leukemogenesis in acute promyelocytic leukemia. PMID: 27888400
7. DNA methyltransferase 3A promotes cell proliferation by silencing CDK inhibitor p18INK4C in gastric carcinogenesis PMID: 26350239
8. Data suggest that cell cycle-dependent kinase inhibitors CDKN2C/p18 and CDKN1A/p21 facilitate cell cycle entry/cell proliferation of quiescent adult human pancreatic beta cells in primary culture (from tissues obtained from organ donors). PMID: 26740620
9. Mutations in CDKN2C is associated with sporadic parathyroid adenoma. PMID: 24127162
10. Analysis of B1a lymphocyte phenotypes of p18-deficient C57BL/6 mice finds that p18 is a key regulator of the size of the B1a cell pool. PMID: 22896639
11. up-regulated HULC promotes proliferation of hepatoma cells through suppressing p18 PMID: 22685290
12. Data indicate that the role of CDKN2C in the adverse outcome of cases with hemizygous deletion was less certain. PMID: 21994415
13. results demonstrate for the first time that N-Myc is a downstream target of RET2A signaling, and propose that induction of N-Myc by RET2A is a key step leading to lower p18 levels during MEN2A tumorigenesis PMID: 21112821
14. conclude that E2F proteins and Sp1 play an important role in the control of p18 expression PMID: 12077144
15. Deletions in the CDKN2C locus and hypermethylation in the CDKN2C promoter region play a role in ovarian granulosa cell tumorogenesis. PMID: 12203782
16. p18INK4c may function as a tumor suppressor in Hodgkin lymphoma, and inactivation may contribute to cell cycle deregulation and defective terminal differentiation of the Reed-Sternberg cells. PMID: 14645011
17. protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c) PMID: 15107819
18. p18(INK4C) loss may contribute to medulloblastoma formation in children PMID: 16260494
19. oncogenic RET and loss of p18 cooperate in the multistep tumorigenesis of medullary thyroid carcinoma PMID: 18316595
20. NaBu-mediated p18( INK4C ) regulation played a role in cell cycle arrest and erythroid differentiation in K562 cells. PMID: 18642058
21. deletions of CDKN2C are important in the progression and clinical outcome of myeloma PMID: 18829482
22. P18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma PMID: 18942719
23. Purpose was to investigate genetic alterations of CDKN2C gene in 38 pituitary adenomas. The absence of CDKN2C protein was correlated with LOH of the CDKN2C locus on chromosome 1 and with methylation of the CDKN2C promoter. PMID: 18973139
24. The down-regulation of p18(INK4C) expression may contribute to the tumorigenesis of pituitary adenomas. PMID: 19401813
25. p18(INK4C) is a downstream target of GATA3, constrains luminal progenitor cell expansion, and suppresses luminal tumorigenesis in the mammary gland PMID: 19411068
26. Results identified a molecular basis for CDK inhibitors to exert an antitumor effect in p18-deficient cancers and support the clinical use of CDK inhibitors. PMID: 19509251

Show More

Hide All

HGNC: 1789

OMIM: 603369

KEGG: hsa:1031

STRING: 9606.ENSP00000262662

UniGene: Hs.525324